[1]刘韵琳,刘可欣,刘学,等.基于内皮功能调控探讨培元降压方干预大鼠高血压模型作用机制[J].陕西中医,2025,46(11):1462-1468.[doi:DOI:10.3969/j.issn.1000-7369.2025.11.004]
　LIU Yunlin,LIU Kexin,LIU Xue,et al.Mechanism of Peiyuan Jiangya formula in intervening hypertensive model rats based on endothelial function regulation[J].,2025,46(11):1462-1468.[doi:DOI:10.3969/j.issn.1000-7369.2025.11.004]
点击复制

基于内皮功能调控探讨培元降压方干预大鼠高血压模型作用机制
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年11期
页码:
1462-1468
栏目:
基础研究
出版日期:
2025-11-05

文章信息/Info

Title:
Mechanism of Peiyuan Jiangya formula in intervening hypertensive model rats based on endothelial function regulation
作者:
刘韵琳1; 刘可欣1; 刘学1; 冯银1; 范小璇1; 2
（1.陕西中医药大学第一临床医学院，陕西 咸阳 712046；2.陕西中医药大学附属医院，陕西 咸阳 712000）
Author(s):
LIU Yunlin1; LIU Kexin1; LIU Xue1; FENG Yin1; FAN Xiaoxuan1; 2
（1.The First Clinical Medical College of Shaanxi University of Chinese Medicine,Xianyang 712046，China；2.Affiliated Hospital of Shaanxi University of Chinese Medicine,Xianyang 712000，China）
关键词:
高血压; 培元降压方; 血管内皮损伤; 一氧化氮; 氧化应激; 内皮型一氧化氮合酶/一氧化氮通路; 一氧化氮合酶抑制模型
Keywords:
Hypertension; Peiyuan Jiangya formula; Vascular endothelial dysfunction; Nitric oxide; Oxidative stress; Endothelial nitric oxide synthase/Nitric oxide pathway; Nitric oxide synthase inhibition model
分类号:
R 544.1
DOI:
DOI:10.3969/j.issn.1000-7369.2025.11.004
文献标志码:
A
摘要:
目的：探讨培元降压方对N-硝基-L-精氨酸甲酯（L-NAME）诱导的高血压模型大鼠的降压作用及其对血管内皮功能的保护机制。方法：32只SD大鼠随机分为四组：空白组、模型组、培元降压方组及天麻钩藤饮组，每组8只。除空白组外，其余各组灌胃L-NAME 50 mg/(kg·d)，连续4周建立高血压模型。造模成功后，给予相应药物干预8周。实验期间监测大鼠一般状态及血压，干预结束后采用离体血管环评估血管舒张功能；HE染色观察肠系膜动脉组织形态；ELISA检测血清一氧化氮（NO）、血管内皮生长因子（VEGF）、内皮素（ET-1）水平；荧光检测法检测血管活性氧（ROS）含量；Western blot检测主动脉组织中内皮型一氧化氮合酶（eNOS）及其磷酸化（p-eNOS）蛋白表达。结果：治疗8周后，与模型组比较，培元降压方组降低了高血压大鼠血压（P＜0.01），增强血管内皮依赖性舒张反应，改善血管内皮损伤，提高血清NO、VEGF含量，降低ET-1含量，减少组织中活性氧生成水平，促进主动脉组织中eNOS及p-eNOS蛋白表达，差异有统计学意义（均P＜0.01）。结论：培元降压方对L-NAME诱导的高血压大鼠具有一定的降压效果，并能有效改善血管内皮功能。培元降压方通过调控NO/ET-1平衡、减轻氧化应激水平，激活eNOS/NO信号通路，发挥降压及血管保护作用。
Abstract:
Objective:This study aimed to investigate antihypertensive effect of Peiyuan Jiangya formula on L-NAME-induced hypertensive rat models and its protective mechanism on vascular endothelial function.Methods:32 SD rats were randomly divided into four groups:blank group,model group,Peiyuan Jiangya formula group and Tianma Gouteng decoction group,with 8 rats in each group.Except for the blank group,the other groups were intragastrically administered L-NAME at 50 mg/(kg·d) for 4 consecutive weeks to establish the hypertensive model.After successful modeling,the corresponding drugs were administered for 8 weeks.During experiment,the general condition and blood pressure of the rats were monitored.After the intervention,vascular dilation function was evaluated by isolated vascular rings.The morphology of mesenteric artery tissue was observed by HE staining.The levels of serum nitric oxide (NO),vascular endothelial growth factor (VEGF),and endothelin-1 (ET-1) were detected by ELISA.The content of reactive oxygen species (ROS) was detected by fluorescence detection.The expression of endothelial nitric oxide synthase (eNOS) and its phosphorylation (p-eNOS) in aortic tissue was detected by Western blot.Results:After 8 weeks of treatment,compared with the model group,the Peiyuan Jiangya formula group significantly reduced blood pressure in hypertensive rats (all P＜0.01),enhanced endothelium-dependent vasodilation,improved vascular endothelial injury,increased serum NO and VEGF levels,decreased ET-1 levels,reduced the generation of reactive oxygen species in tissues,and promoted the expression of eNOS and p-eNOS in aortic tissue，differences statistically significant (all P＜0.01).Conclusion:Peiyuan Jiangya formula has certain antihypertensive effect on L-NAME-induced hypertensive rats and can effectively improve vascular endothelial function.It exerts antihypertensive and vascular protective effects by regulating the NO/ET-1 balance,reducing oxidative stress levels,and activating eNOS/NO signaling pathway.

参考文献/References:

[1]INOUE T.Unawareness and untreated hypertension:A public health problem needs to be solved[J].Hypertens Res:off J Jpn Soc Hypertens,2025,48(4):1639-1642.
[2]POLACZYK M,OLSZANECKA A,WOJCIECHOWSKA W,et al.Multiple drug intolerance in patients with arterial hypertension:Prevalence and determining factors[J].Pol Arch Intern Med,2023,133(3):16399.
[3]中国高血压防治指南修订委员会,高血压联盟(中国),中国医疗保健国际交流促进会高血压病学分会,等.中国高血压防治指南(2024年修订版)[J].中华高血压杂志（中英文）,2024,32(7):603-700.
[4]SHAFER B M,KOGAN S A,MCHILL A W.Pressure building against the clock:The impact of circadian misalignment on blood pressure[J].Curr Hypertens Rep,2024,26(1):31-42.
[5]HENEIN M Y,VANCHERI S,LONGO G,et al.The impact of mental stress on cardiovascular health-part Ⅱ [J].J Clin Med,2022,11(15):4405.
[6]孙黎明,夏晓露,马红萍.高尿酸血症与高血压及心血管疾病关系研究进展[J].陕西医学杂志,2024,53(2):286-289.
[7]刘可欣,李凯,冯银,等.基于血管重塑理论探讨脉络学说对早期高血压的防治[J].辽宁中医药大学学报,2025,27(5):89-93.
[8]刘慧琳,倪世豪,张小娇,等.基于隐结构模型结合关联规则分析杨忠奇教授治疗高血压病的方药规律[J].中国中药杂志,2025,50(10):2865-2874.
[9]李吉旭,张林,李财,等.半夏白术天麻汤治疗H型高血压Meta分析[J].陕西中医,2022,43(8):1122-1127.
[10]陈泽豪.电针颈段夹脊穴对L-NAME诱导的高血压大鼠降压效应及其机理研究[D].延吉:延边大学,2024.
[11]李仪奎.中药药理实验方法学[M].上海:科学技术出版社,2006:1088-1090.
[12]刘靖.应重视中青年单纯舒张期高血压的防治[J].中华高血压杂志,2022,30(11):1001-1003.
[13]李晓阁.硫化氢对L-NAME诱导的高血压大鼠血压昼夜节律的调控及机制研究[D].石家庄:河北医科大学,2022.
[14]王海艳,代迪迪.针刺联合天麻钩藤饮加减治疗眩晕肝阳上亢证疗效研究[J].陕西中医,2024,45(7):985-988.
[15]柳威,邓林华,赵英强.天麻钩藤饮对肾性高血压动物模型的作用机制探讨[J].湖南中医杂志,2021,37(9):164-168.
[16]卿俊,刘平安,鄢然,等.天麻钩藤饮对自发性高血压大鼠血管重塑的抑制作用及对NOX2/ROS通路、内质网应激的影响[J].湖南中医药大学学报,2024,44(12):2150-2156.
[17]许欣颖,胡小海,朱红俊.柴归汤调控环磷酸腺苷/蛋白激酶B信号通路干预原发性高血压大鼠作用机制[J].陕西中医,2024,45(3):313-317.
[18]PANTHIYA L,TOCHARUS J,ONSA-ARD A,et al.Hexahydrocurcumin ameliorates hypertensive and vascular remodeling in L-NAME-induced rats[J].Biochim Biophys Acta Mol Basis Dis,2022,1868(3):166317.
[19]NGUELEFACK-MBUYO E P,SONFACK C S,FOFIE C K,et al.Antihypertensive effect of the stem bark aqueous extract of garcinia lucida vesque (Clusiaceae) in L-NAME-treated rats:Contribution of endothelium-dependent and-independent vasorelaxation[J].Heliyon,2023,9(11):e21896.
[20]YANG X,YANG W,HE S,et al.Danhong formula alleviates endothelial dysfunction and reduces blood pressure in hypertension by regulating MicroRNA 24-phosphatidylinositol 3-kinase-serine/threonine kinase-endothelial nitric oxide synthase axis[J].J Ethnopharmacol,2024,323:117615.
[21]DA SILVA F C,DE ARAUJO B J,CORDEIRO C S,et al.Endothelial dysfunction due to the inhibition of the synthesis of nitric oxide:Proposal and characterization of an in vitro cellular model[J].Front Physiol,2022,13:978378.
[22]DROD D,DROD M,WO JCIK M.Endothelial dysfunction as a factor leading to arterial hypertension[J].Pediatr Nephrol,2023,38(9):2973-2985.
[23]黄自通,杨伟韬,黄晓霞,等.强舒降压方对L-NAME诱导大鼠高血压的干预作用及其机制[J].广东药科大学学报,2022,38(6):74-79.
[24]CAMARDA N,TRAVERS R,YANG V K,et al.VEGF receptor inhibitor-induced hypertension:Emerging mechanisms and clinical implications[J].Curr Oncol Rep,2022,24(4):463-474.
[25]JANASZAK-JASIECKA A,PLOSKA A,WIEROSKA J M,et al.Endothelial dysfunction due to eNOS uncoupling:molecular mechanisms as potential therapeutic targets[J].Cell Mol Biol Lett,2023,28(1):21.
[26]WU Y,DING Y,RAMPRASATH T,et al.Oxidative stress GTPCH1 and endothelial nitric oxide synthase uncoupling in hypertension[J].Antioxid Redox Signaling,2021,34(9):750-764.
[27]WANG Y,ZHANG F,LIU Y,et al.Nebivolol alleviates aortic remodeling through eNOS upregulation and inhibition of oxidative stress in l-NAME-induced hypertensive rats[J].Clin Exp Hypertens,2017,39(7):628-639.

相似文献/References:

[1]杨 敏,姜钧文,肖 蕾.中医体质与急性心肌梗死及其危险因素的相关性研究*[J].陕西中医,2019,(4):437.
　YANG Min,JIANG Junwen,XIAO Lei..Study on the correlation between constitution of traditional Chinese medicine and acute myocardial infarction and its risk factors[J].,2019,(11):437.
[2]高京宏,于 龙 △,王翠娟.大秦艽汤治疗颈椎病性高血压临床研究[J].陕西中医,2019,(5):597.
　GAO Jinghong,YU Long,WANG Cuijuan..Clinical observation of Daqinjiao decoction in the treatment of cervical spondylotic hypertension[J].,2019,(11):597.
[3]侯红霞,张春红.熄风通络汤联合西药治疗对高血压患者血管内皮功能的影响*[J].陕西中医,2019,(7):875.
　HOU Hongxia,ZHANG Chunhong..Effects of Xifeng Tongluo decoction combined with western medicine on vascular endothelial function in patients with hypertension[J].,2019,(11):875.
[4]钱卫东,侍煜景△.宁脉安神颗粒治疗女性更年期高血压疗效及对患者中医证候、血压变异性的影响*[J].陕西中医,2019,(9):1202.
　QIAN Weidong,SHI Yujing..Effects of Ningmai Anshen granule on TCM syndrome and blood pressure variability in women with climacteric hypertension[J].,2019,(11):1202.
[5]郭春霞,陈震霖△.中医从心肝肾论治高血压病现代作用机制及优势探讨*[J].陕西中医,2020,(5):650.[doi:DOI:10.3969/j.issn.10007369.2020.05.027]
　GUO Chunxia,CHEN Zhenlin..Study on Modern mechanism and advantage of TCM treating hypertension on aspects of the heart,liver and kidney[J].,2020,(11):650.[doi:DOI:10.3969/j.issn.10007369.2020.05.027]
[6]钟 路,尹胡海,黄 婕,等.从热毒学说论治高血压*[J].陕西中医,2020,(8):1131.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.032]
　ZHONG Lu,YIN Huhai,HUANG Jie,et al.Treatment of hypertension by heat toxicology[J].,2020,(11):1131.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.032]
[7]朱舜明,张学军,张荣怀,等.生脉注射液联合靶剂量比索洛尔对高血压伴心力衰竭患者血管内皮功能和心功能的影响*[J].陕西中医,2020,(10):1403.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.017]
　ZHU Shunming,ZHANG Xuejun,ZHANG Ronghuai,et al.Effects of Shengmai injection combined with target dose bisoprolol on vascular endothelial function and cardiac function in patients with hypertension and heart failure[J].,2020,(11):1403.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.017]
[8]欧阳雅蓉,傅为武,黄彩依,等.自噬在高血压靶器官损害中的作用及中医药治疗研究进展*[J].陕西中医,2020,(11):1669.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.040]
[9]王辞晓,赵良斌,黄佑群.益气活血补肾方联合厄贝沙坦对高血压性肾损害患者肾功能的保护作用[J].陕西中医,2021,(6):735.[doi:DOI:10.3969/j.issn.1000-7369.2020.06.014]
　WANG Cixiao,ZHAO Liangbin,HUANG Youqun.Protective effect of Yiqi Huoxue Bushen recipe combined with irbesartan on renal function in patients with hypertensive renal damage[J].,2021,(11):735.[doi:DOI:10.3969/j.issn.1000-7369.2020.06.014]
[10]邱思婕,李新梅.平肝化痰法联合西药治疗老年高血压疗效及对患者血压变异性、臂踝脉搏波传导速度、踝臂指数的影响[J].陕西中医,2021,(8):1056.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.017]
　QIU Sijie,LI Xinmei.Clinical curative effect of Pinggan Huatan method combined with western medicine on elderly hypertension and its influences on blood pressure variability,brachial-ankle pulse wave velocity and ankle-brachial index[J].,2021,(11):1056.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.017]

备注/Memo

备注/Memo:
国家自然科学基金资助项目（82374548）；国家中医药管理局高水平中医药重点学科建设项目（国中医药人教函〔2022〕226号）；陕西省中医脑病临床医学研究中心项目（陕科社发〔2017〕176号）；陕西省血管老化和神经退行性疾病中西医防治创新团队项目（2022-SLRH-LJ-015)
更新日期/Last Update: 2025-11-04